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ABSTRACT 
WILLIAM EVANS SISTRUNK: Histone Deacetylase Inhibitors and Breast Cancer 
Metastasis: A Review and Exploration of HDACi(s) and other Chemotherapeutic Agents 
(Under the direction of Dr. Yu-Dong Zhou and Dr. Dale G. Nagle) 
 
 The traditional perspective of Histone Deacetylase enzymes is focused around 
their inherent epigenetic modification characteristics. While it is true that the histone 
modification these enzymes exhibit play a role in cancer and related diseases, Histone 
Deacetylase has a variety of non-histone targets. The non-histone targets include 
microtubules and are of specific interest because of the microtubules’ role in cell line 
differentiation, replication, apoptosis, and cancer metastasis. Using a variety of Histone 
Deacetylase Inhibitors (HDACi) and other chemotherapeutic compounds, our research 
group explored the HDACi effect on breast cancer cell lines. Our goal was to indicate the 
presence of HDACi cell-line dependent cancer growth inhibition and to study the 
hypothesized non-histone mechanism of microtubule modification in HDACi(s). The 
experiment consisted of three parts: viability assay, clonogenic assay, and combination 
assay which analyzed HDACi(s) possible synergistic character with microtubule 
stabilizing compounds. The specific breast cancer cell lines used were MDA-MB-231 
clones LM-4175 and BOM-1833, and MCF7-BOM. The results of our experiments 
indicated that there was cell line dependent growth inhibition with the treatment of 
HDACi(s). Specifically, MCF7-BOM showed to be more susceptible to treatment, and 
this could be due to it being an estrogen receptor positive ER+ cell line. However, the 
growth inhibition never reached complete inhibition and was most prominent at the 
highest concentrations of HDACi(s). Higher concentrations of HDACi(s) also had the 
most prominent effect on colony growth inhibition in the clonogenic assay. The 
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combination assay had an interesting result indicating an antagonistic trend between 
microtubule stabilizers and HDACi(s).  
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Introduction: Breast Cancer 
 A profound statement that has resonated with me throughout my undergraduate 
research came from a newly diagnosed breast cancer patient named Carol. She described 
her first reaction like many of us would, “Why me?”; However, Carol’s next thought 
was, “Why not me?” (37). Unfortunately, Carol is correct in that the incidence of breast 
cancer does not discriminate among women. In other words, all have an absolute risk of 
developing the disease in their lifetime. Currently, one out of every eight women develop 
one of the many forms of breast cancer in their lifetime (15). That number is expected to 
increase as screening methods advance and progress throughout the world. Some experts 
predict that there will be 3.2 million new cases per year by 2050 compared to the 
1,384,155 new cases registered in 2008 (29).  
 The emergence of cancer is simply a misprint of DNA. Imagine a cell as a 
factory containing thousands of printing presses. The assembly of pages (DNA) copied 
from the press (template strand DNA) is essentially the same process in which the body 
replicates DNA. However, that is just one factory; the body has an estimated 10^13 or 
thirty trillion cells in the body (17). Therefore, it is a question of when, not if, 
cancerous errors will occur. The human body has complex mechanisms known and 
unknown to correct these errors or apoptosis (self-terminate) corrupted cells. Despite 
this, an accumulation of errors ranging from single digits to thousands of misprints can 
develop into cancer. In the case of breast cancer, there are specific factors both non-
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modifiable and modifiable that can increase the risk of developing the disease (15). 
Non-modifiable factors or factors that cannot be controlled include age, race, genes, age 
of menopause, breast density, body height, hormones, and prior history of breast biopsy 
or benign tumors. Before the age of 30, women have a very small chance of developing 
breast cancer. However, from the ages of 30 to 50 years of age, there is a dramatic 
increase of disease incidence that remains elevated after the age of 50 (15). Race and 
genetic factors are especially critical in addressing an individual’s chances of breast 
cancer. Caucasian women over the age of 50 have an incidence rate of 351.9 per 
100,000-compared to 292.2 per 100,000 African American women in the same age range 
(15). One of the most well-known breast cancer genetic mutations is BRCA 1 and BRCA 
2. According to the Center for Disease Control, 50 out of 100 women with these 
mutations will develop breast cancer by the age of 70 (CDC). Thus, preemptive measures 
such as Mastectomy (removal of breast tissue) become a desirable choice in these hyper-
predisposed women. Physical and chemical characteristics of an individual such as breast 
density, hormone levels, age of menopause, etc. can cause variability in breast cancer 
incidence. For instance, research suggests that the delay in menopause results in a 3% 
increase of breast cancer for every year of absence (15). 
 Unlike non-modifiable factors that are uncontrollable, modifiable factors such as 
smoking, diet and exercise, environment, and hormone therapies can be controlled to 
reduce the breast cancer risk. High alcohol consumption in an individual’s diet is the 
most heavily correlated lifestyle factor associated with the risk of breast cancer (15). 
According to one study, alcohol consumption is the primary cause in 4% of new breast 
cancer diagnoses (27). Overall, modifiable risks other than alcohol consumption have a 
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marginal increase in breast cancer incidence. However, it is important to consider that 
avoiding known harmful modifiable factors can prevent a significant proportion of 
postmenopausal breast cancer cases (28).  
Although breast cancer is unfortunately common among women, the prognosis 
is very heterogenous as each diagnosis depends on certain conditions. Tumor 
morphology, genetic typing, and histological grade coalesce in outcomes ranging from 
treatable to extremely malignant (29). Cancerous breast tumors are divided into several 
categories including infiltrating ductal carcinoma, infiltrating lobular carcinoma, 
tubular, mucinous, medullary, adenoid cystic carcinoma, and many other types (29). 
Each type of breast cancer has unique characteristics determining prognosis. For 
example, smaller tubular carcinomas are associated with a less advanced stage or 
progression at presentation of disease compared to infiltrating ductal carcinomas (29). 
The presence of estrogen receptors (ER positive) in a cancerous cell morphology 
indicates favorable outcomes (1). Also, the presence of genes that code for proteins 
such as HER2 (Human Epidermal Growth Factor Receptor 2) in tumor cells adds 
another trait in which physicians and scientists must consider for treatment. In contrast 
with ER positive breast cancer, Triple-Negative breast cancer (TNBC) is characterized 
with poor outcomes and high rates of relapse (8). The TNBC cells lack HER2 protein 
receptors, estrogen receptors, and progesterone receptors. In essence, the most effective 
way to destroy tumors is to consider them unique individuals through personalized 
medicine. This ideology centers around the mantra that there is both inter-heterogeneity 
among tumor types and intra-heterogeneity within the tumor itself (4). Ultimately, the 
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goal is to identify the breast cancer type and best course of treatment before the disease 
is in its final stage.  
What is final stage breast cancer? What aspect of the disease ultimately causes 
death? These were two of my very first questions in the initial segment of research. The 
simple answer is that metastasis or M-stage is the final progression of breast cancer. 
Metastasis is the process in which cancerous cells spread to other parts of the body 
through the blood or lymph circulatory systems. Furthermore, the new tumor formed is 
of the same type as the primary tumor. For example, if cancerous cells spread from a 
breast tumor to the brain, these cancerous cells are still breast tissue (26). Distant 
metastases such as mentioned above (breast to brain) is the main cause of death in 
breast cancer patients (5).  
Metastatic or malignant tumors can cause death in a variety of ways depending 
on where the secondary tumors form. For example, malignant tumors are highly 
metabolic and can not only become strenuous to maintain but consume surrounding 
normal cells to strengthen their viability. Metastasis also causes terminal complications 
by interfering with bodily functions such as the immune system and circulatory system. 
Secondary infections, strokes, and other serious medical conditions resulting from the 
secondary tumor interference are the ultimate cause of death (30). Under these 
circumstances, a patient that has progressed to M-stage breast cancer is at a much 
higher risk than previous stages. Consequently, preventing the malignant 
transformation of a primary tumor is a promising target for therapy. Under the guidance 
of Dr. Yu-Dong Zhou and Dr. Dale G. Nagle, I along with my collaborators Mary 
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Grace Stewart and Henry Nguyen have pursued drug therapies using Histone 
Deacetylase Inhibitor (HDACi) class compounds to prevent malignant breast cancer.  
 
Histone Deacetylase Inhibitors (HDACi) 
 The Human Genome Project represents a new era in the advancement of medicine. 
Using the combined resources of collaborators from around the world, in 2003 the 
entirety of the Human Genome was sequenced (25). In essence, the instruction manual 
of every cell in the human body is now available to be studied and perhaps manipulated. 
However, it is important to note that while some genes are constantly transcribed, many 
remain silent depending on the cellular environment and cell type. The gatekeepers of 
transcription are the histone proteins (3). Histones are proteins that have between 145-
147 DNA base pairs wrapped around the core histone protein. Each core histone protein 
is globular in structure and consists of two histone protein subunits: H2A, H2B, H3, and 
H4 (3). The histone is designed to be post-translationally modified by the acetylation of 
lysine residues by histone acetylases (HATS). This function allows the histone to loosen 
the DNA tightly wrapped around the core protein and enable transcription to occur (3). 
 Imagine being able to control the acetylation of histones and eventually 
manipulate the phenotype of a cell without changing its inherent genotype. In 1977, 
scientists were able to complete such a feat by converting a cancerous erythroleukemia 
cell line into a non-dividing hemoglobin synthesizing cell using butyric acid, a histone 
deacetylase inhibitor (HDACi) (11). In order to change the cell in such a drastic way, the 
histone proteins must be denied the ability to be deacylated, which is the exact goal of 
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histone deacetylase inhibitors. The mechanism of HDACi consists of inhibiting the 
histone deacetylase enzyme’s function of removing the acetyl group from lysine residues. 
With the HDAC inhibited by the HDACi, the histone acetylases can freely function to 
stimulate the transcription of DNA through the unwinding effect of the histone. Also, it 
is especially important to note that HAT and HDAC enzymes have non-histone targets 
in the cell. When HDACi(s) are introduced into the cell, the effects on both the histone 
and non-histone proteins coalesce into increased cell apoptosis, decreased migration, 
decreased proliferation, and cellular differentiation (32). 
  
Figure 1 (20) 
 One pivotal question regarding the HDACi mechanism is: How do 
noncancerous cells (and some cancerous) survive the hyperacetylation of histones that 
cause the destruction/differentiation of many forms of cancer cells? While a concrete 
answer is unknown, one study suggests that body cells have an innate response to 
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downregulate histone acetylases during a period of hyperacetylation caused by HDACi 
(12). This theory is supported by histone acetylation falling dramatically after cells 
were removed from a HDACi rich environment. In other terms, the lack of HDACi 
induced hyperacetylation in the new environment post-HDACi caused an 
overcompensation of the innate cellular defense. How did this innate defense arise? 
Interestingly, HDACi activity is observed in many natural products produced by 
bacteria. Eukaryotic cells that were in the presence of these bacteria and thus the 
HDACi developed this innate response over thousands of generations in order to 
survive. The human body even has HDACi activity present in the large intestine where 
bacteria are believed to act as a weapon against eukaryotic organisms competing for the 
same resources (12).  
 Histone Deacetylase enzymes are a very diverse group of molecules affecting 
many components of the cell and body. In fact, there are four classes each representing 
numerous subtypes: HDAC class I, consisting of HDAC 1,2,3,8. HDAC class II(a), 
consisting of HDAC 4,5,6, and 7. HDAC class II(b), consisting of HDAC 6 and 10. 
HDAC class IV, contains HDAC 11 (10). While each HDAC subtype has many 
functions, the most crucial to my research are HDAC 1, 2, and 6. HDAC 1 and 2 are 
intricate in the processes of cell proliferation and apoptosis. The overexpression of 
HDAC 1 and 2 are associated with many forms of cancer including breast, lung, and 
classical Hodgkin’s lymphoma (2). HDAC 6 is mostly present in the cytoplasm and is a 
target of α-tubulin. The HDAC 6 mechanism with chaperon protein Hsp90 is known to 
increase the growth of some forms of prostate and breast cancer. HDAC 6 is also 
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associated with oral squamous cell carcinoma and expression increases in advanced stage 
cancers in comparison to early stage (2).  
 One of the non-histone targets of HDAC 6—as mentioned previously—is alpha-
tubulin. Microtubules have a complex mechanism of elongation and degradation that 
enable cells to be motile in their external and internal environment. The acetylation of α-
tubulin has a stabilizing effect that leads to long lived, less motile, and less dynamic 
microtubules (6). In contrast, HDAC 6 upregulation causes the deacetylation of 
microtubules that is associated with cell invasion and metastasis. Therefore, compounds 
inhibiting HDAC 6 are promising potential therapeutic agents for preventing metastasis 
in late stage cancers (6).  
 What is the current state of HDACi(s) in the clinical treatment of cancer? Four 
HDACi compounds have been FDA approved: Vorinostat (SAHA), Romidepsin, 
Panobinostat, and Belinostat. Vorinostat inhibits class I, II, and IV HDAC molecules and 
is approved for treatment of Cutaneous T-cell Lymphoma (CTCL). Romidepsin inhibits 
class I HDAC molecules and is approved for treatment of CTCL. Panobinostat inhibits 
class I, II, and IV HDAC molecules and is approved for treatment of CTCL and multiple 
Myeloma. Lastly, Belinostat inhibits class I, II, and IV HDAC molecules and is approved 
for treatment of Peripheral T-cell Lymphoma (PTCL) (17). The common denominator for 
each FDA approved HDACi(s) is that they are effective in the treatment of non-solid 
tumors (Myeloma, Lymphoma). While this clinical use is promising, one of the most 
exciting characteristics of HDACi(s) is its ability to work synergistically with other 
chemotherapeutic agents (7). HDACi(s) in combination with other epigenetic modifiers, 
reactive oxygen species, protease inhibitors, DNA damaging agents, and microtubule 
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stabilizers have increased chemotherapeutic effects. While numerous studies support the 
synergistic effect, the mechanism is generally unknown (7).  
 In the experiments the research group conducted, we examined the relationship of 
Histone Deacetylase Inhibitors and other chemotherapy agents on multiple breast cancer 
cell lines. The purpose of the viability, combination, and other cell assays was to replicate 
and further understand the therapeutic effect of HDACi(s) on breast cancer.  
 
Histone Deacetylase Inhibitor Experiment 
  The experimental timeline and progression that has encompassed over two years 
began in the fall of 2016 under the direction of Dr. Nagle and Dr. Zhou. The first section 
was a seminar class that introduced new researchers to the many intricacies of breast 
cancer and beyond. The second section was devising a research plan in order to 
understand the effects of Histone Deacetylase Inhibitors on specific breast cancer cell 
lines. The HDACi research plan consisted of background research, viability assay, 
combination assay, and clonogenic assay. While it was a general goal to study all 
HDACi(s), HDAC 6 inhibitors were of specific interest because of the non-histone 
microtubule targets it influences. Therefore, microtubule stabilizers and destabilizers 
were used in viability studies as well as in combination with HDACi(s) to study this 
effect. Our general hypothesis stated HDACi(s) may exhibit cell-line dependent 
inhibitory activity against breast cancer cells.  
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MATERIALS AND METHODS 
Background Research 
 In the spring of 2017, after the decision to pursue HDACi(s) with a concentration 
of the anticancer effects of HDAC 6 inhibitors, the initial plan of research was to conduct 
a background review on the topic. This process was completed in three steps: literature 
review, survey known HDACi/chemotherapy compound data, and selection of cell 
lines/compounds. Dr. Zhou emphasized the importance of literature review before 
conducting our experiment in order to maximize our chances of originality in the field. 
While it is difficult to produce new data because of the constant global competition, 
literature review was helpful because we could determine what had been researched and 
use that knowledge to focus on the selection of our topic. We learned that the role of 
HDAC 1, 2, and 3 and the inhibition of these HDACs in the treatment of breast cancer 
have been researched frequently in studies conducted over five years ago (22). However, 
we also learned more about HDAC 6 and the HDAC 6 inhibitor’s role in microtubule 
stability (6). Since HDAC 6 interacts with microtubules, Dr. Zhou suggested using an 
HDAC 6 inhibitor in conjunction with paclitaxel and other microtubule stabilizers and 
destabilizers. In essence, there could be a synergistic property associated with the 
addition of HDAC 6 inhibitors with classic chemotherapy agents such as paclitaxel. 
 The next step of the background review was to survey known chemotherapy 
compounds and their inhibitory effects on each cell line. This procedure was completed 
using the National Cancer Institute Developmental Therapeutic Program named NCI-60 
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Human Tumor Cell Line Screen. The NCI-60 cell line assay results function as a 
database for the compound concentration needed to reach LC50 (LC50 is the lethal dose 
in which 50% of cells are destroyed in a given amount of time) in a particular cell line. In 
each compound our group was interested in, we would use the NCI-60 panel data to 
determine the general concentrations needed to reach LC50 and in turn determine a 
general guideline for the quantity of compound needed in our experiment.  
 Compounds were selected to fill five classes of HDACi(s) and microtubule 
stabilizers/destabilizers: HDAC 1 and 2 inhibitors, HDAC 6 inhibitors, microtubule 
stabilizers, microtubule destabilizers, and pan-HDAC inhibitors. Among the compounds 
selected to fulfill these categories, further selections were based on logistics and 
availability of the compound.  
Compound Data 
Drug Classification Compound Name Purchased from Solubility/stock solution 
HDACi 1 and 2 Romidepsin Cayman 100 µM 
HDACi 6 Ricolinostat Selleck 10 mM 
MT Stabilizer Paclitaxel Sigma 10 mM 
 Epothilone B Selleck 10 mM 
MT Destabilizer Colchicine Sigma 100 µM 
 Vinblastine Sigma 100 µM 
Pan-HDACi Vorinostat (SAHA) Cayman 10 mM 
 Panobinostat Cayman 100 µM 
Figure 2 
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Molecular Structure  
 
Romidepsin 
 
Ricolinostat 
 
Paclitaxel 
 
Epothilone B 
 
Colchicine 
 
Vinblastine 
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Vorinostat (SAHA) 
 
Panobinostat 
Figure 3 
Preparation of HDACi and Chemotherapy Agent Dilution Plate 
The chemotherapeutic agents were purchased from Cayman Chemical, Sigma-
Aldrich, or Selleck Chemical. For our experiments, we set the stock solution 
concentration of 10 mM or 100 µM for each compound. Specific amounts of DMSO 
were added to each chemotherapeutic agent in order to configure the stock solution 
concentrations from the variable factory purchased compound concentrations. Serum free 
media was used to dilute the stock solutions to the highest tested concentration, and this 
was set at 2x the final concentration of the mother plate. The mother plate was prepared 
at 3.5x volume (of a single dose) because it was to be used on three SRB viability 96-well 
plates. A 1:10 serial dilution was performed creating a dilution pattern as seen in the table 
below (Top 10,3,1,.3,.1,.03,.01 μM Bottom). This process was completed in a stepwise 
pattern. For example, in one dilution we siphoned 35 μL of 0.1 μM solution into a well of 
315 μL of serum free medium which created 350 μL of diluted solution at 0.01 μM. Each 
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dilution was calculated to have 350 μL of end product in each well.
 
Figure 4: Serial Dilution Example 96-Well Plate 
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Breast Cancer Derived Cell Lines 
 The human breast cancer cell lines used in experimentation was MDA-MB-231, 
MDA-MB-231 subtypes BOM clone 1833 (bone metastasis) and LM clone 4173 (lung 
metastasis), and MCF7-BOM. MDA-MB-231 is a triple negative breast cancer that was 
derived from a pleural effusion in a 51-year-old Caucasian female in the 1970’s (18). 
MDA-MB-231 is an aggressive tumor with poor prognosis which commonly metastasizes 
to the lung and bone to form secondary tumors. MDA-MB-231 BOM and LM are cell 
lines derived from these secondary tumors and were first generated by Dr. J Massagué at 
the Sloan Kettering Cancer Center (21). Our experiments acquired the specific MDA-
MB-231 clones BOM 1833 and LM 4175 from Dr. Konosuke Watabe at Wake Forest 
University. MCF7 is an ER-positive breast cancer cell line that was originally derived 
from a 69-year-old Caucasian female in the 1970’s (18). The MCF7-BOM cells that were 
used in our experimentation are another product of bone secondary metastasis generated 
in Dr. J Massagué’s lab at the Sloan Kettering Cancer Center (23). Our lab acquired 
MCF7-BOM cells from Dr. Konosuke Watabe at Wake Forest University.  
 The MDA-MB-231 (BOM and LM) and MCF7-BOM cell lines were sustained in 
DMEM/F12 media containing L-glutamine (Mediatech, Manassas, VA), enriched with 
10% fetal bovine serum (FBS) (Hyclone, Logan, UT),50 units/mL of penicillin and 50 
µg/mL streptomycin (Gibco, Grand Island, NY) were added, and the cells were 
temperature controlled at 37 °C in an environment of 95% air/5% CO2 (34).  
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Sulforhodamine B (SRB) Viability Assay 
 The SRB viability assay procedure started after the 96-well master dilution plate 
was created and the specific cell lines developed to the desired density. The SRB viability 
assays are a rapid, relatively inexpensive, and reliable test to study the effects of 
particular compounds on cell line proliferation (24). The first step of the process was to 
trypsonize the cell cultures using 1 mL (Trypsin) and then wash the cells with 10 mL of 
10% fetal bovine serum (FBS) media. The cells were then diluted with additional 10% 
FBS media until a density of 3 million cells per mL of 10% FBS was reached using a 
hemocytometer. Next, 100 µL of cell solution and 100 µL of media were seeded to each 
well in the desired number of 96-well plates (depending on the specific trial 
requirements) at a concentration of 30,000 cells per well. The plates were cultured at 37° 
C within a humid environment of 95% air and 5% C02. The 96-well cell containing plates 
were then infused with a specific amount of chemotherapy agent in the 96-well master 
dilution plate. The combination chemotherapy agent/cell plates were incubated for 48 
hours. After the incubation process was complete, 100 µL of media was withdrawn from 
each well. The wells began the fixation process with the addition of 100 µL of 20% 
trichloroacetic acid (TCA) and 1% PBS solution to each well. The fixed plates were 
placed in the refrigerator for one hour at 4°C. After removal from the refrigerator, the 
plates were washed with tap water four times and set aside to dry. Each well was then 
stained using 100 µL of .4% SRB (w/v, 1% acetic acid) for 10 minutes at room 
temperature. The plates were further washed with 1% acetic acid four times and set aside 
to dry. Tris Base (100 µL of 10 mM) was added to each of the stained wells, and the 
plates were lightly shaken for 10 minutes using the microplate genie. The plates were 
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then read using the SpectaFlour plate and Magellen software at an absorbance range of 
496-620 nm. The SRB dye binds to the basic amino acids present in the cell proteins 
allowing for Magellan software to calculate the inhibition value. This inhibition value 
was generated by the software using the total protein mass per well (flagged by the 
SRB dye) which is proportional to the cell density of that cell.  
 
Combination Assay 
 One of the main objectives of these series of experiments was to explore the 
synergistic or possibly antagonistic effects of HDACi(s) and other chemotherapeutic 
compounds. Therefore, a combination assay was conducted using a cross of HDACi 
compounds and microtubule stabilizing chemotherapeutic agents’ paclitaxel and 
epothilone B. The procedure of the combination assay was very similar to the viability 
assays performed. The difference was the bidirectional compound addition where the 
microtubule stabilizers (Taxol and epothilone) were added from left to right and the 
HDACi(s) (romidepsin, ricolinostat, panobinostat) were added from top to bottom. The 
specific HDACi(s) tested were chosen based on the range of HDACi activity they 
exhibit. Romidepsin is a class 1 HDACi that showed strong and consistent activity in 
our viability screening. Ricolinostat is a class 6 HDAC inhibitor and was selected 
because of our interest in its specific effect on microtubule stabilization and 
destabilization. Panobinostat was selected because it is a pan-HDACi, meaning it 
inhibits all classes of HDAC. The concentration ranges for both HDACi(s) and 
microtubule stabilizers were determined based on concentrations used in the National 
Cancer Institute Database of both experimental and physiological relevance.  
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Combination 
Assay 
Romidepsin 
    V             V           V 
    V             V           V 
Ricolinostat 
  V         V          V 
  V         V          V 
Panobinostat 
    V        V             V           V 
    V        V            V           V 
Taxol 0 
nM   ===> 
0.001 µM 0.01 
µM 
0.1 
µM 
0.1 
µM 
1 
µM 
10 µM 0.0001 
µM 
0.001 
µM 
0.01 
µM 
0.1 µM 
Taxol 10 
nM     ===> 
0.001 µM 0.01 
µM 
0.1 
µM 
0.1 
µM 
1 
µM 
10 µM 0.0001 
µM 
0.001 
µM 
0.01 
µM 
0.1 µM 
Taxol 
100 nM   ===> 
0.001 µM 0.01 
µM 
0.1 
µM 
0.1 
µM 
1 
µM 
10 µM 0.0001 
µM 
0.001 
µM 
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Figure 5: Combination Dilution 96-Well Plate  
Clonogenic Assay 
The Clonogenic assay is used in assessing the survivability of a cell line in the 
presence of a cytotoxic agent. Essentially, the ability for a single cell to grow into a 
colony under cytotoxic conditions (9). The number of six-well plates used was a total of 
six: three for the BOM and three for MCF7-BOM cell lines. The first plate in each cell 
line had two media control wells and four chemotherapeutic compound wells. The second 
and third plates of each cell line had all six wells containing chemotherapeutic 
compounds. The concentrations of the chemotherapeutic agents were based on 
physiological relevance (low concentration) and cytotoxic potential (high concentration). 
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Chemotherapeutic  
Compound 
Cytotoxic Potential Physiological  
Relevance  
Vorinostat (SAHA) 10 µM 1.0 µM 
Ricolinostat 10 µM 1.0 µM 
Romidepsin 0.01 µM 0.001 µM 
Panobinostat 0.1 µM 0.01 µM 
Paclitaxel 1.0 µM 0.1 µM 
Epothilone B 0.01 µM 0.001 µM 
Colchicine 0.1 µM 0.01 µM 
Vinblastine 0.1 µM 0.01 µM 
Figure 6 
The cells were seeded in a density of 3,000 cells per well, and six-well plates 
were incubated for four hours at 37°C allowing the cells to adhere. After a period of 24 
hours, the media solution was replenished with fresh FBS (10%) with antibiotics. This 
incubation process was then conducted over ten days with fresh medium replenished 
every five days. After the incubation period, the cells were fixed with methanol and 
stained using crystal violet solution (1 mg/mL in 20% ethanol). Pictures of the final 
Clonogenic assay product were taken on an iPhone XR.  
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Results and Discussion 
SRB Viability Assay 
 The results of the Sulforhodamine B viability assay reflect the percent inhibition 
values of the chemotherapeutic agents tested on MDA-MB-231 BOM, MDA-MB-231 
LM, and MCF7-BOM cell lines. The initial goal of viability testing was to acquire an 
IC50 value (drug concentration where cell growth is inhibited by half of total inhibition). 
However, while our results had significant inhibition, they never reached this value. 
Instead, our group categorized each chemotherapeutic drug into a highest inhibitory 
concentration category under the parameters of cell line, percent inhibition, and drug 
concentration of highest inhibition. The highest inhibitory concentration results and 
trends of the viability tests are located in the figures below. The graphs were configured 
using prism GraphPad 8.  
 
Highest Inhibitory Concentration  
Chemotherapeutic 
Agent  
LM BOM MCF7-BOM 
Con [ ] % Inhibit Con [ ] % Inhibit Con [ ] % Inhibit 
Vorinostat (SAHA) 10 µM 58 3 µM 24 10 µM 48 
Ricolinostat 10 µM 51 10 µM 29 10 µM 42 
Panobinostat 0.1 µM 52 0.1 µM 34 0.1 µM 29 
Romidepsin 0.1 µM 50 0.1 µM 36 0.1 µM 46 
Vinblastine  0.1 µM 38 0.1 µM 28 0.1 µM 16 
Colchicine 0.1 µM 30 0.1 µM 22 0.1 µM 44 
Epothilone B 0.1 µM 39 0.1 µM 31 0.1 µM 41 
Paclitaxel  10 µM 47 10 µM 33 10 µM 47 
Figure 7 
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Figure 8 
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 In the Highest Inhibitory Concentration table, the cells that were highlighted 
represent values in which the greatest growth inhibition was not at the highest 
concentration of chemotherapeutic agent tested. However, in the case of epothilone B, 
inhibition was relatively similar across all cell lines from the lowest to highest 
concentration. The results were conflicting in the MDA-MB-231 BOM vorinostat 
(SAHA) data. The first and second highest concentrations tested were relatively similar, 
possibly indicating a plateau in inhibitory effect at these concentrations. Further testing 
for both MDA-MB-231 BOM vorinostat (SAHA) and epothilone B SRB viability would 
be ideal to further specify the data.  
 An interesting aspect of our results was the sensitivity of the MCF7-BOM cell 
line compared to the MDA-MB-231 BOM and LM cell lines. There was a consistent 
trend of MCF7-BOM being the most susceptible or a close second in every trial. This 
could be due to the MCF7-BOM cell lines being estrogen receptor positive (ER+) 
compared to the triple-negative cell lines of MDA-MB-231 BOM and LM. One previous 
study found that HDACi enhances ER(+)-stress mediated cell death in some cancers (14). 
That being said, one of the highest percent inhibition values was romidepsin, a HDAC 1 
and 2 inhibitor, at 74% inhibition in the MCF-7 BOM cell line. Interestingly, the HDAC 
6 inhibitor ricolinostat had the most effect on the MCF-7 BOM cell line with a sharp 
slope. This finding could be promising as a higher drug concentration could lead to 
increased cell growth inhibition. Overall, there is a clear (though somewhat small) 
inhibitory effect of HDACi(s) on these specific breast cancer cell lines.  
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There was a second round of SRB viability testing conducted on the MDA-MB-
231 BOM cell line in order to replicate our findings in the first viability experiment and 
to fine tune our laboratory skills in the viability procedure.  In general, our results were 
very similar to the original MDA-MG-231 BOM viability assay. The epothilone B assay 
exhibited a high inhibition at both low and high concentrations, and the other drug assays 
exhibited similar inhibitory effects. However, there were a few differences that are 
noteworthy. First, the percent inhibition values were larger in general. These numbers 
could be caused from a variety of reasons including the cell line being weakened 
(stressed) to begin with and/or our lab technique was slightly superior in delivering the 
chemotherapeutic agents. Second, romidepsin and panobinostat exhibited around 0% 
inhibition at their highest concentration. This finding directly contradicts the first 
viability experiment and is most likely an error in the lab. More testing is required to 
clarify the contradiction of results.  
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Clonogenic Assay 
               BOM                                               MCF-7 BOM 
  
   
   
Figure 10 
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 The figures above represent two three-plate clonogenic assays on the MDA-MB-
231 BOM cell line and MCF-7 BOM. In a general visual comparision of the two plates, 
relativly similar clonogenic inhibition occurred between the two cell lines. This tends to 
suggest that there is relativly little cell line dependence in clonogenic inhibition between 
the two cell lines. What is interesting is the difference between the physiologically 
relevent concentration inhibition of HDACi(s) and the cytotoxic potential. In every 
HDACi physiological (lower) concentration well, there was some form of colony growth. 
On the other hand, cytotoxic potential concentrations of HDACi exhibited virtually 
complete colony growth inhibition. The only other chemotherapuetic compounds that had 
such inhibition were the microtubule stabilizers paclitaxel and epothilone B at both 
physiological and cytotoxic relevence. This HDACi concentration dependent colony 
growth inhibition could be due to the microtubule stabilizing or destabilizing effect 
taking place at the cytotoxic potential concentration. In essence, the microtubule effect of 
HDACi(s) (as suggested by previous studies) could be exhibiting the same properties as 
epothilone B and paclitaxel (6). Overall, the clonogenic assay provided further evidence 
of the inhibitory effects that HDACi(s) have on breast cancer cell lines. It also suggests 
further avenues of research regarding HDACi(s) effect on microtubule destabilization or 
stabilization.  
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Combination Assay 
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Figure 11, 12, 13 
 The goal of the combination assays conducted was to determine the possible 
synergistic or antagonistic effects associated with the combination of these 
chemotherapeutic compounds. The results obtained were then compared to the US 
National Cancer Institute’s Combination Almanac. This reference system provides 
previous crosses of the compounds of interest in a variety of cell lines. However, the 
crosses in the almanac are not necessarily the same as our experiment. Therefore, some 
direct comparisons are not possible.  
The combination assay represented in figure 11 is a cross between panobinostat 
(pan-HDAC inhibitor), epothilone B, and paclitaxel in two different cell lines: MDA-
MB-231 BOM and MCF7-BOM. In comparing the two cell lines, there also was 
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relatively little cell line dependent inhibition. There was only a slight variation in 
magnitude where every trend is the same.  
In both cell lines, the panobinostat-paclitaxel cross and the panobinostat-epothilone B 
inhibition cross percent inhibition values were highest when panobinostat was at 0.001 
µM across all ranges of microtubule stabilizer concentrations. In regard to the 
synergistic or antagonistic characters of these compounds in combination, there is an 
antagonistic relationship between panobinostat-paclitaxel and panobinostat-epothilone 
B. This is evident because of the decrease in percent inhibition as the microtubule 
stabilizer concentration increased along with the increase in concentration of HDACi.  
 The combination Assay represented in figure 12 is a cross between ricolinostat 
(HDAC 6 Inhibitor), epothilone B, and paclitaxel. The same cell lines were used in 
figure 12 as figure 11. In comparison between MDA-MB-231 BOM and MCF7-BOM, 
there is no evidence of cell line dependent inhibition. After discussion within the 
research group, we concluded that the graphs represented are abnormal. In both 
paclitaxel-ricolinostat and epothilone B-ricolinostat crosses, the results at high 
combination are sporadic and vary. This could be due to cell line stress, human lab 
error, or an unknown factor. However, a general antagonistic trend can be seen in both 
crosses as the microtubule stabilizer concentration increases and HDACi concentration 
increases.  
 The combination assay represented in figure 13 is a cross between romidepsin 
(HDAC 1 and 2 Inhibitor), epothilone B, and paclitaxel. The same cell lines were used 
in figure 13 as figures 11 and 12. There is also a similar effect as seen in figures 11 
and 12 in that there is no cell line dependent inhibition between MDA-MB-231 BOM 
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and MCF7-BOM. In the paclitaxel-romidepsin cross, the highest inhibiting 
combination of compounds were present at 0.001 µM across all ranges of paclitaxel. 
There was also a strong antagonistic trend that increased when paclitaxel 
concentrations were elevated and romidepsin concentrations were elevated. In this 
particular cross, there had been previous data on the NCI Almanac reference tool. 
According to the reference, both MCF7 and MDA-MB-231 cell lines showed an 
antagonistic relationship (NCI). This provided some validation to our group as we 
were able to compare similar research to our own data. The epothilone B-romidepsin 
cross had the highest inhibition values at 0 µM romidepsin in high concentrations of 
epothilone. It appeared that romidepsin and epothilone B had an antagonistic 
relationship similar to previous trends of the other compound combinations. However, 
these were some of the most antagonistic as there was a sharp decline in inhibition at 
the highest concentrations of epothilone B and romidepsin.  
 Overall, there was an antagonistic trend with the increased concentrations of 
microtubule stabilizers and HDACi(s). This was also supported by relevant data at the 
NCI Combination Almanac. However, our data should be supplemented in the future 
by a replicate number of n=3 compared to our n=2. There could be many possible 
answers to why this antagonistic trend occurs. One answer could be a microtubule 
destabilizing effect that is present in HDACi competing with the microtubule 
stabilizing compounds. In order to answer this question, further research must be 
conducted on HDACi(s) effect on microtubules.  
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Conclusion 
 In reflecting on the analysis of the SRB viability assays, clonogenic assays, and 
combination assays across a variety of cell lines, our hypothesis that histone 
deacetylase inhibitors have cell line-dependent inhibition is supported. In the MDA-
MB-231 clones BOM-1833 and LM-4175 as well as MCF7-BOM breast cancer cell 
lines, there was a variation in inhibitory effects in SRB viability testing. This could be 
due to the presence of ER receptors. However, more research must be conducted and 
higher concentrations should be tested in order to find the IC50 values of the 
HDACi(s) tested. The clonogenic assay also provided evidence of HDACi tumor 
growth inhibition. At the cytotoxic potential or highest concentration, HDACi(s) had a 
great degree of colony growth inhibition. However, at physiologically relevant 
concentrations, there was only mild inhibition. When HDACi(s) were combined with 
the microtubule stabilizers epothilone B and paclitaxel, an antagonistic trend was 
observed. Therefore, this combination may not be desired for chemotherapeutic 
therapy. However, this evidence provides another step in understanding the non-
histone targets of HDACi(s) and their role in microtubule stabilization and 
destabilization. In order to further this experiment, fluorescent labeling of 
microtubules and other structure proteins would benefit the understanding of this 
potential mechanism.  
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